Frontlight ResearchEarly access
TerminatedNo phase
The Leaflex™ Standalone Study Protocol
Key facts
- Who runs it
- Pi-cardia
- Where
- Hungary1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 33 people enrolled
- Started
- 2 Sept 2020
- Ended
- 14 Aug 2024
- Type of study
- Interventional
- Treatments tested
- Leaflex™ Performer
- Record updated
- 28 February 2025
- Why it stopped
- The study was terminated after completion of the Exploratory phase due to reprioritization of attention and resources by Sponsor.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Patient with symptomatic, severe aortic stenosis who are not recommended by the heart team for immediate treatment with surgical or transcatheter aortic valve replacement
- Patient is willing to comply with scheduled visits and tests and is able and willing to provide informed consent
Who cannot take part
- Coronary, carotid, or vertebral artery disease that, in the opinion of the heart team, should be treated; or treatment of coronary artery disease ≤ 1 month prior to index procedure
- Aortic balloon valvuloplasty ≤ 3 months prior to index procedure
- Stroke ≤ 12 months prior to index procedure
- History of a myocardial infarction ≤ 6 weeks prior to index procedure
- Ongoing severe infection, including endocarditis, or sepsis
- Patients with clinically significant abnormality in cell blood count, history of bleeding diathesis or coagulopathy
- Left ventricle ejection fraction <30%
- Moderate or greater aortic regurgitation
- Anatomic contraindications
- Hemodynamic instability
- Hypertrophic cardiomyopathy with obstruction
- Life expectancy ≤ 12 months
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A prospective, multicenter, single-arm study aimed to assess safety and performance of the Leaflex™ Performer in the treatment of patients with symptomatic, severe aortic stenosis.
Read full original descriptionShow less
Subjects will be seen at pre- and post procedure, discharge, 30 days and at 3, 6, 9 and 12 months post procedure.
The group in the trial
- Leaflex™ PerformerTreatment being tested
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 28 February 2025